Investor Newsletter

Issue 04 2022

MicroPort®

Three MicroPort® Products Win iF Design Award

Three products of MicroPort Scientific Corporation (MicroPort®) have won the iF Design Award 2022, which was recently announced after more than 10,000 entries from 57 countries were evaluated.

The awarded products are: the Honghu Orthopedic Surgical Robot developed by Shanghai Microport MedBot (Group) Co., Ltd. (MicroPort® MedBot®), the disposable peroral cholangioscopy catheter developed by MicroPort Urocare (Jiaxing) Co., Ltd. (MicroPort® Urocare) and the Lingli Smart Stethoscope developed by Shanghai Duowen Medtech Co., Ltd. (Duowen Medtech). The three winning products were unanimously recognized by the international jury in all five criteria of idea, form, function, impact, and differentiation.

MicroPort

Firehawk Liberty™ Receives Registration Approval in Peru

The Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), developed by Shanghai MicroPort Medical Group Co., Ltd. (MicroPort®), recently received registration approval from the General Directorate of Medicine, Supplies and Drugs (DIGEMID) in Peru.

The approval of Firehawk Liberty™ in Peru marks that MicroPort® will continuously deepen the globalised branding and operation strategy based on local language families by consistently implementing the operation model of "globalisation in operational strategy, localised implementation, deployment with diversification, and unified positioning", thereby realising global deployment through effective integration of resources and markets around the world, which in turn will bring the products of MicroPort® to more countries or regions and benefit patients and doctors around the world.



MicroPort®

First Homegrown MRI-Conditional Pacemaker of MicroPort® MSC Receives NMPA Approval for Marketing

MicroPort Soaring CRM (Shanghai) Co., Ltd. (MSC) has recently received the approval from China's National Medical Products Administration (NMPA) for its Rega™ MRI-conditional implantable pacemakers. The Rega™ pacemaker series, which features advanced AutoMRI™ technology, is the first in China that is compatible with magnetic resonance imaging (MRI) examinations. Its launch will benefit more patients with pacemakers who require MRI exams for various reasons.

Mr. Jack Zhu, General Manager of MSC, commented, "The AutoMRI™-enabled MRI-conditional pacemaker is another major breakthrough for MSC after years of commitment in the field of cardiac rhythm management. As MSC's first MRI-conditional pacemakers, Rega™ will provide more options for clinical practices. MSC has been dedicated to the development and manufacture of medical devices linked to cardiac rhythm management since its founding in 2014, and has built a team with industry experience and strong R&D capabilities. MSC will continue to establish itself in the local market, fulfill clinical needs, and quickly deliver a family of heart rhythm management solutions to enable more patients with cardiac rhythm disorders to regain their health and improve their quality of life."

MicroPort

MicroPort® CRM receives MRI-conditional CE mark for Ulys™ and Edis™ ICDs as well as for Gali™ CRT-Ds

MicroPort® CRM, a pioneering company in the field of Cardiac Rhythm Management, recently received CE Mark approval under the new Medical Device Regulation (MDR – 2017/745) for MRI conditionality on Ulys™ and Edis™ Implantable Cardiac Defibrillators (ICDs), as well on Gali™ and Gali SonR™ devices indicated for Cardiac Resynchronization Therapy and Defibrillation (CRT-Ds).

Benoît Clinchamps, President of MicroPort® CRM, stated, "MicroPort® CRM is committed to developing technologically advanced devices that are both lifesaving and beneficial to physicians and patients alike. With that commitment in mind, we have endeavored to make Ulys™, Edis™ and Gali™ MRI conditionality retro-active on eligible configurations. It is a great satisfaction to have achieved this."

MicroPort

Endovastec™ Holds Virtual Launch Meeting for Fontus™ Branched Surgical Stent Graft System

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently hosted a product launch event titled “Elephant trunk for the heart: revival of the classic” for its Fontus™ Branched Surgical Stent Graft System (Fontus™), which was held back-to-back with a seminar on the stented elephant trunk procedure. Twenty-one experts from 17 hospitals gathered virtually to share clinical data and information related to the application of Fontus™, which attracted the attendance of over 5,000 viewers online.

At the product launch, Prof. Lizhong Sun, the creator of Sun's Procedure, said, "With the popularity of stented elephant trunk procedure, many companies around the world are developing surgical stent for the treatment of Stanford type A aortic dissection. The emergence of the new Fontus™ stent by Endovastec™ follows the trends of international research and further promotes the development of this specific area in China. ”

Mr. Qing Zhu, President of Endovastec™, introduced the background of Fontus™’s development and the eight-year development process. He stated, "Fontus™ is the first branched surgical stent graft ever approved for marketing in China and even globally. The launch of Fontus™ represents another step forward in the treatment of aortic disease. We hope that Fontus™ will provide clinicians with more strategic surgical options and a more convenient surgical experience that will benefit more patients with aortic disease.”



Endovastec™ Receives MDSAP Certificate for Brazil and Japan

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently announced that it has received a Medical Device Single Audit Program (MDSAP) certificate from the Technischer Überwachungs-Verein (TÜV SÜD), an international notified body, certifying Endovastec™'s compliance with both ISO13485:2016 standards and the regulatory requirements in Brazil, and Japan, which lays the groundwork and provides the momentum for the company's global development.

Obtaining the MDSAP quality system certificate will make Endovastec™ products more advantageous and accessible in international markets, helping the company accelerate its worldwide expansion strategy. The company's global operations span 18 countries and regions across Europe, South America, and Asia Pacific. Its flagship products, including the Minos® Abdominal Aortic Stent-Graft and Delivery System, the Hercules® Thoracic Stent Graft System, and the Castor® Branched Aortic Stent-Graft System, have all been available in many overseas markets worldwide. The Hyperflex® Balloon Catheter has been approved in Japan recently.

MicroPort

MicroPort NeuroTech™ Receives NMPA Marketing Approval for the X-track™ Intracranial Distal Access Catheter

MicroPort NeuroTech Limited (MicroPort NeuroTech™) has received marketing approval issued by China's National Medical Products Administration (NMPA) for its independently-developed X-track™ Intracranial Distal Access Catheter (X-track™).

The launch of X-track™ as the first intermediate catheter product for the treatment of cerebrovascular acute ischemic stroke of the company, further enriches MicroPort NueroTech™'s product portfolio for ischemic stroke treatment, combined with Neurohawk® Stent Thrombectomy Device, Diveer® Intracranial Balloon Catheter and APOLLO™ Intracranial Stent System. In the future, MicroPort NueroTech™ will continue to promote product innovation and will keep improving its inclusive and accessible total medical solutions for hemorrhagic stroke, intracranial atherosclerotic stenosis, and acute ischemic stroke.

MicroPort

MicroPort® Honghu Orthopedic Surgical Robot Obtains Marketing Approval from NMPA

Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®) recently announced that its Honghu Orthopedic Surgical Robot (MicroPort® Honghu) developed by Suzhou MicroPort® OrthoBot Co., Ltd. (MicroPort® OrthoBot), a wholly-owned subsidiary of MicroPort® MedBot®, has received approval for marketing by China's National Medical Products Administration (NMPA), making it the first approved orthopedic surgical robot equipped with a proprietary robot arm developed by a Chinese company. The approval of MicroPort® Honghu will further break the monopoly of imported products on the domestic orthopedic joint robot market, promote the rapid development of smart orthopedic surgery robots designed and developed in China, further realize precision medicine, and create conditions for the promotion of surgical robot technology in primary hospitals to benefit more patients.

Dr. Chao He, President of MicroPort® MedBot®, stated, "As the third approved flagship product of MicroPort® MedBot®, MicroPort® Honghu opens a new chapter of our strategic plan in the field of orthopedics. It will provide doctors with a precise, intelligent, friendly and convenient surgical experience and contribute to the promotion of surgical robotic technology at the grassroots level. In the future, MicroPort® MedBot® will continue to adhere to medical-industrial cooperation, gradually increase its coverage of clinical applications, promote synergy, accelerate incremental development of technology, industrialization and commercialization of high-end homegrown surgical robots, and provide intelligent total solutions for robotic surgery that prolong and reshape life."



MicroPort

MicroPort® MedBot® Robotic-Assisted Trans-bronchial Navigation System Used in First Clinical Trial

The MicroPort® Trans-bronchial Surgical Robot, a robotic-assisted bronchoscopy navigation system jointly developed by Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®), West China Hospital of Sichuan University (WCH), and Shanghai Chest Hospital, was used in a robot-assisted trans-bronchial biopsy for lung nodules, which was performed by Prof. Weimin Li, Prof. Dan Liu and their team at WCH. As a first-in-man lung biopsy trial assisted by a domestic bronchial robot, the biopsy marks the first breakthrough in the field of non-invasive natural orifice transluminal surgeries using a homegrown surgical robot.

President Weimin Li commented, “It has been a major challenge for doctors to improve the diagnostic rate of peripheral lung cancer using conventional bronchoscopy. The MicroPort® Trans-bronchial Surgical Robot is able to access deeper lung tissue and accurately biopsy micronodules, allowing for the diagnosis of lung cancer at an earlier stage. As a leading base for medical scientific research and technological innovation in China, WCH has been committed to promoting domestic medical technology innovations through collaboration between doctors and engineers. Early screening and precise treatment of lung cancer can considerably increase patients' chances of survival and enhance their quality of life. We hope that through the collaboration with MicroPort® MedBot®, we can achieve early and precise diagnosis and treatment of lung cancer and improve the survival rate of patients with lung cancer. ”

Dr. Chao He, President of MicroPort® MedBot®, stated, "The completion of this first robotic-assisted bronchoscopy is a significant milestone in medicine-engineering collaboration on domestic innovative medical devices, as it not only fills a gap in the field of diagnosis and treatment robots for trans-bronchial lung diseases, but also represents a significant breakthrough in the field of non-invasive natural orifice transluminal robots. As an innovative leader in China’s surgical robot industry, we will accelerate the clinical application and technology development of this product, promoting the commercialization of the total solution of intelligent surgical robots for lung diseases. At the same time, we will take this as a fresh starting point for expanding clinical applications in the realm of natural orifice transluminal interventions. Such technologies can be used not just for respiratory procedures, but will also be gradually used in other natural orifice transluminal therapies in the future, such as gastrointestinal and reproductive system therapies, providing accessible, inclusive and total robotic solutions for smart surgeries. ”

Investor Newsletter

Issue 04 2022

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com